Core One Labs Inc. (CLABF)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Apr 28, 2026, 4:00 PM EST
Core One Labs Revenue
In the fiscal year ending March 31, 2023, Core One Labs had annual revenue of 458.54K CAD, down -29.25%. Core One Labs had revenue of 93.66K in the quarter ending December 31, 2023, a decrease of -17.22%.
Revenue
458.54K CAD
Revenue Growth
-18.65%
P/S Ratio
0.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
47.00 USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mymetics | 564.14K |
| Baudax Bio | 1.27M |
| Panacos Pharmaceuticals | 99.00K |
| Genocea Biosciences | 1.91M |
| Synovics Pharmaceuticals | 19.09M |
| Athersys | 80.00K |
| Gelesis Holdings | 12.14M |
Core One Labs News
- 7 months ago - CSE Bulletin: Delist - Core One Labs Inc. (COOL) - Newsfile Corp
- 1 year ago - Core One Enters into Loan Agreement with Right Season Investments - Accesswire
- 2 years ago - Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market - Accesswire
- 2 years ago - Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods - Accesswire
- 2 years ago - Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease - Accesswire
- 2 years ago - Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass - Accesswire
- 2 years ago - Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease - Accesswire
- 3 years ago - Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds - Accesswire